Developer docs
API playgroundTry for free, no card

Search company profiles

ARS Pharmaceuticals

Full company profile

uuid00000oy

Namestring
ARS Pharmaceuticals
Legal namestring
ARS Pharmaceuticals, Inc.
Websiteurl
ars-pharma.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

ARS Pharmaceuticals (Nasdaq: SPRY) is a publicly traded specialty pharmaceutical company founded in 2015 and headquartered in San Diego, California. The company develops and commercializes neffy, the first and only FDA-approved needle-free intranasal epinephrine spray for emergency treatment of Type I allergic reactions including anaphylaxis. Neffy's proprietary technology is built around Intravail (dodecyl-maltoside), a patented absorption agent that enables injection-like pharmacokinetics through nasal administration, paired with a delivery device reporting 99.999% dose-delivery reliability. The product targets approximately 40 million people in the United States with severe allergies, of whom only about 3 million currently hold an epinephrine prescription and an estimated 80-90% do not carry or administer their device as indicated due to needle aversion and device inconvenience.

The revenue model combines direct U.S. commercial sales through wholesale distributors (McKesson, Cardinal Health, Cencora, Anda) and specialty pharmacy channels with international licensing partnerships (ALK-Abelló for Canada, Pediatrix Therapeutics for China). For the full year 2025, ARS reported total revenue of $84.3 million, of which $72.2 million was U.S. neffy net product sales; Q1 2026 revenue reached $22.7 million, a 124% year-over-year increase. Patient access is supported by the neffyConnect co-pay and patient-assistance program and a direct cash-pay channel that became a focal point after PBM coverage was denied. Commercial operations are built around a 148-person specialty sales force (targeting 150 in Q2 2026) directed at allergists, emergency physicians, and pediatricians, supplemented by direct-to-consumer, celebrity (Drew Brees), medical-conference, and community (neffyInSchools) initiatives.

Capital structure reflects a November 2022 merger with Silverback Therapeutics that delivered over $280 million in cash and securities and created the public Nasdaq listing, an August 2021 $55 million Series D led by SR One with participation from RA Capital and Deerfield, and an October 2025 $250 million loan facility to fund commercialization. The company holds regulatory approvals for neffy in the United States, Canada, China (NMPA, December 2025), and the European Union (EURneffy 1 mg and 2 mg), and is advancing a Phase 2b pipeline program for chronic spontaneous urticaria with interim data expected in Q4 2026.

Short descriptiontext

ARS Pharmaceuticals (Nasdaq: SPRY) is a specialty pharmaceutical company that develops and commercializes neffy, the first FDA-approved needle-free intranasal epinephrine spray for emergency treatment of severe allergic reactions, serving roughly 40 million Americans with Type I allergies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
epinephrine nasal spray, allergy therapeutics, anaphylaxis treatment, needle-free drug delivery, intranasal pharmaceuticals
Industry2 codes
PRIMARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAIAD
Needle-Free Injection Systems (Jet Injectors/Microneedle Patches)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
NAICS code1 code
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Epinephrine Nasal Spray (Allergy Therapeutics)
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Neffy product sales
TypeOne Time License
Description

Commercial revenue from neffy U.S. net product sales following FDA approval. Q1 2026 revenue of $22.7M including $17.5M in neffy net product revenue, up 124% year-over-year. Full year 2025 revenue of $84.3M with neffy generating $72.2M in U.S. net product revenue.

biospace.com
2International licensing and milestones
TypeLicensing Royalties
Description

Upfront payments, regulatory milestones, and sales milestones from international partners. Received $155M in upfront and milestone payments from ALK-Abelló for Canada licensing with potential for up to $310M in additional regulatory and sales milestones. $4M regulatory milestone from China approval with potential for up to $80M plus tiered royalties.

in.investing.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels7 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Marketing or Sales, Technology or R&D, Operations, Supply Chain
Pricing details2 tiers
1Commercial insurance co-pay program
ModelOtherBilling cadencePay-as-you-go
Notes

Eligible patients with commercial insurance may pay as little as $0 with the co-pay savings program through neffyConnect

ars-pharma.com
2Patient Assistance Program
ModelOtherBilling cadencePay-as-you-go
Notes

Program provides medically necessary neffy free of charge to qualifying applicants based on eligibility criteria

ars-pharma.com
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1neffyConnect
Description

Patient support and financial assistance program for neffy, providing medication fulfillment, financial support, insurance navigation, and access barriers assistance

ars-pharma.com
+3 more records
Core offering1 text field

ARS Pharmaceuticals manufactures and commercializes neffy, the first and only FDA-approved needle-free intranasal epinephrine spray for emergency treatment of Type I severe allergic reactions including anaphylaxis in adults and children weighing at least 33 lbs. Available in 1mg and 2mg doses, neffy uses the proprietary Intravail (dodecyl-maltoside) absorption agent to deliver epinephrine with injection-like pharmacokinetics through nasal administration, addressing the gap where 80-90% of prescribed patients do not carry or use auto-injectors due to needle fear. The company also supports patient access through co-pay programs (neffyConnect) and a K-12 schools donation program (neffyInSchools).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 124% year-over-year revenue growth in Q1 2026
+2 more records
Product overview1 text field

ARS Pharmaceuticals commercializes neffy (epinephrine nasal spray), the first FDA-approved needle-free epinephrine product for emergency treatment of severe allergic reactions including anaphylaxis. The portfolio consists of the core neffy product available in 1mg and 2mg doses, supported by the neffyConnect patient assistance program for access and affordability, and the neffyInSchools community initiative distributing free product to U.S. schools. The company is also advancing its intranasal epinephrine technology into chronic spontaneous urticaria through a Phase 2b pipeline program.

Product and service1 record
1neffy (epinephrine nasal spray)
CategoryCore Pharmaceutical Product
Description

FDA-approved needle-free intranasal epinephrine spray for emergency treatment of Type I severe allergic reactions including anaphylaxis in adults and children weighing 33 lbs or greater. Available in 1mg and 2mg doses, it uses the proprietary Intravail (dodecyl-maltoside) absorption agent to deliver injection-like pharmacokinetics via nasal administration through a device with a 99.999% dose-delivery track record. It targets the approximately 40 million Americans with severe allergies, of whom only 3 million currently hold an epinephrine prescription, addressing the gap where 80-90% of prescribed patients fail to carry or administer auto-injectors due to needle fear.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Drew Brees
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-06-04
Description

Celebrity collaboration to raise awareness about severe food allergies and epinephrine treatment options. Brees, who has food allergies himself, participates in education initiatives emphasizing preparedness and emergency response. Campaign aims to improve timely treatment for allergic reactions.

stocktitan.net
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-11-01
Description

Exclusive licensing agreement for neffy commercialization in Canada. ARS Pharma received $155 million in upfront and milestone payments and is eligible for up to $310 million in additional regulatory and sales milestones. Health Canada approved neffy on April 15, 2026, with expected launch summer 2026, potentially benefiting over 2.5 million Canadians with severe allergies.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Licensing agreement for neffy commercialization in China. China's NMPA approved neffy 2mg on December 29, 2025. ARS Pharma received $4 million regulatory milestone payment with potential for up to $80 million plus tiered royalties in additional milestones. Product expected spring 2026 in China.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Viatris markets EpiPen, the dominant epinephrine auto-injector and ARS Pharma's primary direct competitor in emergency anaphylaxis treatment. Comparable in therapeutic area, prescriber base, and patient population, though Viatris operates broadly across generics and branded pharma.

TypeDirect peer
Description

Kaleo manufactures Auvi-Q, a competing compact epinephrine auto-injector with voice-prompt instructions, directly competing with neffy for allergist prescriptions and school stocking contracts in the U.S. emergency epinephrine market.

TypeBroad incumbent
Description

Emergent BioSolutions operates in the emergency countermeasure space with epinephrine-related products. ARS's CCO previously led commercial initiatives there. Comparable in addressing acute allergic and emergency-response therapeutics.

TypeDirect peer
Description

Amphastar manufactures specialty injectable pharmaceuticals including epinephrine and other emergency-use injectables. It is comparable as a specialty pharma with similar injectable/epinephrine product focus and FDA-approved manufacturing footprint.

TypeDirect peer
Description

Dynavax is a commercial-stage biopharma specializing in allergy-adjacent vaccines (HEPLISAV-B). ARS's new President Donn Casale was CCO there. Comparable as a public, U.S.-based commercial biopharma scaling a single-category product to specialty prescribers.

TypeRegional player
Description

ALK-Abelló is ARS's Canadian licensing partner for neffy and a global leader in allergy immunotherapy. Comparable in allergy-focused therapeutics and serves a similar allergist channel, though its primary franchise is sublingual immunotherapy rather than emergency epinephrine.

TypeDirect peer
Description

Adapted into Emergent BioSolutions, NARCAN nasal spray pioneered needle-free community-use emergency therapeutics. ARS's CCO previously led NARCAN's commercial launch, making it a directly comparable needle-free emergency medication franchise targeting lay users.

TypeBroad incumbent
Description

Teva markets authorized generic epinephrine auto-injectors that compete with EpiPen and by extension neffy. Comparable as a high-volume manufacturer of epinephrine injectables supplying retail and institutional pharmacy channels.

TypeBroad incumbent
Description

Seqirus, a CSL subsidiary, distributes Auvi-Q in the U.S. and operates broadly in vaccines and specialty therapeutics. Comparable as a distributor and channel partner for emergency epinephrine products to allergy specialists and schools.

TypeEmerging player
Description

PharmaTher is developing novel formulations of epinephrine and other emergency-use drugs. Comparable as a small emerging player pursuing differentiated delivery formats in the epinephrine space that may overlap with ARS's intranasal platform strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ARS Pharmaceuticals

Epinephrine Nasal Spray (Allergy Therapeutics)ars-pharma.com

ARS Pharmaceuticals (Nasdaq: SPRY) is a specialty pharmaceutical company that develops and commercializes neffy, the first FDA-approved needle-free intranasal epinephrine spray for emergency treatment of severe allergic reactions, serving roughly 40 million Americans with Type I allergies.

What ARS Pharmaceuticals does

ARS Pharmaceuticals (Nasdaq: SPRY) is a publicly traded specialty pharmaceutical company founded in 2015 and headquartered in San Diego, California. The company develops and commercializes neffy, the first and only FDA-approved needle-free intranasal epinephrine spray for emergency treatment of Type I allergic reactions including anaphylaxis. Neffy's proprietary technology is built around Intravail (dodecyl-maltoside), a patented absorption agent that enables injection-like pharmacokinetics through nasal administration, paired with a delivery device reporting 99.999% dose-delivery reliability. The product targets approximately 40 million people in the United States with severe allergies, of whom only about 3 million currently hold an epinephrine prescription and an estimated 80-90% do not carry or administer their device as indicated due to needle aversion and device inconvenience.

The revenue model combines direct U.S. commercial sales through wholesale distributors (McKesson, Cardinal Health, Cencora, Anda) and specialty pharmacy channels with international licensing partnerships (ALK-Abelló for Canada, Pediatrix Therapeutics for China). For the full year 2025, ARS reported total revenue of $84.3 million, of which $72.2 million was U.S. neffy net product sales; Q1 2026 revenue reached $22.7 million, a 124% year-over-year increase. Patient access is supported by the neffyConnect co-pay and patient-assistance program and a direct cash-pay channel that became a focal point after PBM coverage was denied. Commercial operations are built around a 148-person specialty sales force (targeting 150 in Q2 2026) directed at allergists, emergency physicians, and pediatricians, supplemented by direct-to-consumer, celebrity (Drew Brees), medical-conference, and community (neffyInSchools) initiatives.

Capital structure reflects a November 2022 merger with Silverback Therapeutics that delivered over $280 million in cash and securities and created the public Nasdaq listing, an August 2021 $55 million Series D led by SR One with participation from RA Capital and Deerfield, and an October 2025 $250 million loan facility to fund commercialization. The company holds regulatory approvals for neffy in the United States, Canada, China (NMPA, December 2025), and the European Union (EURneffy 1 mg and 2 mg), and is advancing a Phase 2b pipeline program for chronic spontaneous urticaria with interim data expected in Q4 2026.

ARS Pharmaceuticals firmographics

Firmographics
Name
ARS Pharmaceuticals
Legal name
ARS Pharmaceuticals, Inc.
Website
https://ars-pharma.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Short description
ARS Pharmaceuticals (Nasdaq: SPRY) is a specialty pharmaceutical company that develops and commercializes neffy, the first FDA-approved needle-free intranasal epinephrine spray for emergency treatment of severe allergic reactions, serving roughly 40 million Americans with Type I allergies.
Ownership category
akta.pro rank

ARS Pharmaceuticals industry classification

Industry
Product category
Epinephrine Nasal Spray (Allergy Therapeutics)
NAICS
Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAHAIAK
Nasal Drug Delivery Devices (Sprays/Powder Devices)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAIAD
Needle-Free Injection Systems (Jet Injectors/Microneedle Patches)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Epinephrine nasal spray
  • Allergy therapeutics
  • Anaphylaxis treatment
  • Needle-free drug delivery
  • Intranasal pharmaceuticals

Where ARS Pharmaceuticals is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

ARS Pharmaceuticals business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Marketing or Sales, Technology or R&D, Operations, Supply Chain

Revenue model

  1. Neffy product sales: Commercial revenue from neffy U.S. net product sales following FDA approval. Q1 2026 revenue of $22.7M including $17.5M in neffy net product revenue, up 124% year-over-year. Full year 2025 revenue of $84.3M with neffy generating $72.2M in U.S. net product revenue.
  2. International licensing and milestones: Upfront payments, regulatory milestones, and sales milestones from international partners. Received $155M in upfront and milestone payments from ALK-Abelló for Canada licensing with potential for up to $310M in additional regulatory and sales milestones. $4M regulatory milestone from China approval with potential for up to $80M plus tiered royalties.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goCommercial insurance co-pay program
OtherPay-as-you-goPatient Assistance Program

Go-to-market motion3 records

Distribution channels7 records

Marketing channels7 records

ARS Pharmaceuticals product offering

Product offering

Core offering

ARS Pharmaceuticals manufactures and commercializes neffy, the first and only FDA-approved needle-free intranasal epinephrine spray for emergency treatment of Type I severe allergic reactions including anaphylaxis in adults and children weighing at least 33 lbs. Available in 1mg and 2mg doses, neffy uses the proprietary Intravail (dodecyl-maltoside) absorption agent to deliver epinephrine with injection-like pharmacokinetics through nasal administration, addressing the gap where 80-90% of prescribed patients do not carry or use auto-injectors due to needle fear. The company also supports patient access through co-pay programs (neffyConnect) and a K-12 schools donation program (neffyInSchools).

Product overview

ARS Pharmaceuticals commercializes neffy (epinephrine nasal spray), the first FDA-approved needle-free epinephrine product for emergency treatment of severe allergic reactions including anaphylaxis. The portfolio consists of the core neffy product available in 1mg and 2mg doses, supported by the neffyConnect patient assistance program for access and affordability, and the neffyInSchools community initiative distributing free product to U.S. schools. The company is also advancing its intranasal epinephrine technology into chronic spontaneous urticaria through a Phase 2b pipeline program.

Differentiator

Problem solved

Functional benefit

Brands

  • neffyConnect: Patient support and financial assistance program for neffy, providing medication fulfillment, financial support, insurance navigation, and access barriers assistance
  • neffyinSchools
  • neffy
  • EURneffy

Products and services

  • neffy (epinephrine nasal spray) FDA-approved needle-free intranasal epinephrine spray for emergency treatment of Type I severe allergic reactions including anaphylaxis in adults and children weighing 33 lbs or greater. Available in 1mg and 2mg doses, it uses the proprietary Intravail (dodecyl-maltoside) absorption agent to deliver injection-like pharmacokinetics via nasal administration through a device with a 99.999% dose-delivery track record. It targets the approximately 40 million Americans with severe allergies, of whom only 3 million currently hold an epinephrine prescription, addressing the gap where 80-90% of prescribed patients fail to carry or administer auto-injectors due to needle fear.

Quantifiable outcome

  • 124% year-over-year revenue growth in Q1 2026
  • +2 more outcomes

Companies that use ARS Pharmaceuticals

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

ARS Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

ARS Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor and core.

  • Drew BreesminorGTM or Marketing Partner · 4 June 2026Celebrity collaboration to raise awareness about severe food allergies and epinephrine treatment options. Brees, who has food allergies himself, participates in education initiatives emphasizing preparedness and emergency response. Campaign aims to improve timely treatment for allergic reactions.
  • ALK-Abelló A/ScoreOEM/ Whitelabel/ Licensing Partner · 1 November 2024Exclusive licensing agreement for neffy commercialization in Canada. ARS Pharma received $155 million in upfront and milestone payments and is eligible for up to $310 million in additional regulatory and sales milestones. Health Canada approved neffy on April 15, 2026, with expected launch summer 2026, potentially benefiting over 2.5 million Canadians with severe allergies.
  • Pediatrix TherapeuticscoreOEM/ Whitelabel/ Licensing PartnerLicensing agreement for neffy commercialization in China. China's NMPA approved neffy 2mg on December 29, 2025. ARS Pharma received $4 million regulatory milestone payment with potential for up to $80 million plus tiered royalties in additional milestones. Product expected spring 2026 in China.

Scale indicators16 records

Recent moves7 records

Expansion highlights6 records

ARS Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • Viatris: Viatris markets EpiPen, the dominant epinephrine auto-injector and ARS Pharma's primary direct competitor in emergency anaphylaxis treatment. Comparable in therapeutic area, prescriber base, and patient population, though Viatris operates broadly across generics and branded pharma.
  • Emergent BioSolutions: Emergent BioSolutions operates in the emergency countermeasure space with epinephrine-related products. ARS's CCO previously led commercial initiatives there. Comparable in addressing acute allergic and emergency-response therapeutics.
  • Teva Pharmaceutical: Teva markets authorized generic epinephrine auto-injectors that compete with EpiPen and by extension neffy. Comparable as a high-volume manufacturer of epinephrine injectables supplying retail and institutional pharmacy channels.
  • Seqirus (CSL): Seqirus, a CSL subsidiary, distributes Auvi-Q in the U.S. and operates broadly in vaccines and specialty therapeutics. Comparable as a distributor and channel partner for emergency epinephrine products to allergy specialists and schools.

Direct peers

  • Kaleo (Auvi-Q): Kaleo manufactures Auvi-Q, a competing compact epinephrine auto-injector with voice-prompt instructions, directly competing with neffy for allergist prescriptions and school stocking contracts in the U.S. emergency epinephrine market.
  • Amphastar Pharmaceuticals: Amphastar manufactures specialty injectable pharmaceuticals including epinephrine and other emergency-use injectables. It is comparable as a specialty pharma with similar injectable/epinephrine product focus and FDA-approved manufacturing footprint.
  • Dynavax Technologies: Dynavax is a commercial-stage biopharma specializing in allergy-adjacent vaccines (HEPLISAV-B). ARS's new President Donn Casale was CCO there. Comparable as a public, U.S.-based commercial biopharma scaling a single-category product to specialty prescribers.
  • Adapt Pharma / NARCAN: Adapted into Emergent BioSolutions, NARCAN nasal spray pioneered needle-free community-use emergency therapeutics. ARS's CCO previously led NARCAN's commercial launch, making it a directly comparable needle-free emergency medication franchise targeting lay users.

Regional players

  • ALK-Abelló: ALK-Abelló is ARS's Canadian licensing partner for neffy and a global leader in allergy immunotherapy. Comparable in allergy-focused therapeutics and serves a similar allergist channel, though its primary franchise is sublingual immunotherapy rather than emergency epinephrine.

Emerging players

  • PharmaTher Holdings: PharmaTher is developing novel formulations of epinephrine and other emergency-use drugs. Comparable as a small emerging player pursuing differentiated delivery formats in the epinephrine space that may overlap with ARS's intranasal platform strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks4 records

Key highlights7 records

Customer concentration

ARS Pharmaceuticals social profiles

Digital presence

ARS Pharmaceuticals compliance and trust

Trust signal

Compliance1 record

ARS Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ARS Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles11 records

ARS Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

ARS Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ARS Pharmaceuticals M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ARS Pharmaceuticals

What does ARS Pharmaceuticals do?

ARS Pharmaceuticals manufactures and commercializes neffy, the first and only FDA-approved needle-free intranasal epinephrine spray for emergency treatment of Type I severe allergic reactions including anaphylaxis in adults and children weighing at least 33 lbs. Available in 1mg and 2mg doses, neffy uses the proprietary Intravail (dodecyl-maltoside) absorption agent to deliver epinephrine with injection-like pharmacokinetics through nasal administration, addressing the gap where 80-90% of prescribed patients do not carry or use auto-injectors due to needle fear. The company also supports patient access through co-pay programs (neffyConnect) and a K-12 schools donation program (neffyInSchools).

Is ARS Pharmaceuticals a public or private company?

ARS Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was ARS Pharmaceuticals founded?

ARS Pharmaceuticals was founded in 2015. It employs 101 to 250 people.

Where is ARS Pharmaceuticals based?

ARS Pharmaceuticals is headquartered in San Diego, United States, in the North America region.

How does ARS Pharmaceuticals make money?

Two revenue lines are on record. Neffy product sales are the primary driver. The others are international licensing and milestones.

Who are ARS Pharmaceuticals's main competitors?

Broad incumbents on record are Viatris, Emergent BioSolutions, Teva Pharmaceutical and Seqirus (CSL). Direct peers are Kaleo (Auvi-Q), Amphastar Pharmaceuticals, Dynavax Technologies and Adapt Pharma / NARCAN. ALK-Abelló is listed as a regional player. PharmaTher Holdings is listed as an emerging player.

Does ARS Pharmaceuticals have an API?

No public API is recorded for ARS Pharmaceuticals.

What industry is ARS Pharmaceuticals in?

ARS Pharmaceuticals's product category is Epinephrine Nasal Spray (Allergy Therapeutics). Its primary akta.pro industry code is HLAHAIAK, Nasal Drug Delivery Devices (Sprays/Powder Devices), with a secondary code of HLAHAIAD, Needle-Free Injection Systems (Jet Injectors/Microneedle Patches). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldCenterBook Partners LP Buys 295,532 Shares of ARS Pharmaceuticals, Inc. $SPRYCenterBook Partners LP raised its ARS Pharmaceuticals stake by 239.1% in Q3, buying 295,532 shares. ARS reported a Q3 loss of $0.36 per share and revenue of $37.71 million, missing estimates. The company targets cash-flow breakeven by year-end 2027.American Banking and Market NewsARS Pharmaceuticals, Inc. $SPRY Stock Purchased by CenterBook Partners LPCenterBook Partners LP increased its stake in ARS Pharmaceuticals by 239.1% in Q3, buying 295,532 shares. The company reported a Q3 loss of $0.36 per share, missing the $0.30 consensus, and revenue of $37.71 million fell short of the $41.99 million estimate.The Motley FoolARS Pharma (SPRY) Q3 2026 Earnings Call TranscriptARS Pharma reported Q3 2026 total revenue of $37.7 million, up from $32.5 million a year earlier, with U.S. neffy net product revenue of $33.4 million. The company posted a net loss of $35.6 million, down from $51.2 million in Q3 2025, and reiterated its target to reach cash flow breakeven by year-end 2027.Seeking AlphaARS Pharmaceuticals, Inc. (SPRY) Q3 2026 Earnings Call TranscriptARS Pharmaceuticals reported Q3 2026 results, with CEO Donn Casale outlining a new strategic direction. The company aims to reach cash flow breakeven by year-end 2027 through greater financial discipline. The call also covered the neffy product's market share gains.TradingViewCantor Fitzgerald maintains ARS Pharmaceuticals at Overweight, lowers price target to $20 from $30Cantor Fitzgerald maintained ARS Pharmaceuticals at Overweight and lowered its price target to $20 from $30, a 33.3% decrease. The target implies an upside of 654.7% from the Nov 5 close of $2.65.Investing.comRaymond James downgrades ARS Pharmaceuticals stock rating on weak salesRaymond James downgraded ARS Pharmaceuticals from Strong Buy to Outperform, cutting its price target to $17.00 from $28.00. The stock fell 21.6% in a week after neffy product revenue of $33.4M missed the $38.1M consensus. The firm expects the new management team to need several quarters to implement its strategy.MarketBeatARS Pharmaceuticals Q3 Earnings Call HighlightsARS Pharmaceuticals reported $33.4 million in third-quarter U.S. net product revenue from neffy, reaffirming its goal of cash flow breakeven by end of 2027. The company's neffy market share exceeded 5% and provider prescriptions rose 49% year over year. It expects to complete its commercial reset over the next quarter.MarketBeatARS Pharmaceuticals (SPRY) Expected to Release Quarterly Earnings on ThursdayARS Pharmaceuticals is expected to release Q3 2026 earnings on November 5th, with analysts projecting a loss of $0.34 per share and revenue of $41.99 million. The company's stock opened at $3.66, and analysts have set an average price target of $25.00.American Banking and Market NewsARS Pharmaceuticals (SPRY) Projected to Post Quarterly Earnings on ThursdayARS Pharmaceuticals is expected to report Q3 2026 earnings on November 5th, with analysts projecting a loss of $0.34 per share and revenue of $41.99 million. The company's stock opened at $3.66, and analysts have set an average price target of $25.00.Business & FinancialARS Pharma To Report Third Quarter 2026 Financial ResultsARS Pharma will report its third-quarter 2026 financial results, with dial-in and webcast details provided. The company commercializes neffy, the only needle-free epinephrine approved for anaphylaxis, and is developing ARS-2 for chronic spontaneous urticaria in a Phase 2b trial.